Tirzepatide — the Mounjaro molecule.
Tirzepatide is the dual GLP-1/GIP receptor agonist approved by the FDA as Mounjaro (diabetes) and Zepbound (obesity). As a research peptide in Europe it is available from multiple EU vendors — understanding the difference between research-grade and pharmaceutical-grade is essential.
- Dual GLP-1 + GIP receptor agonist; the same molecule as the approved medicines Mounjaro (diabetes) and Zepbound (obesity).
- SURMOUNT-1 Phase 3 trial reported up to 22.5% mean body-weight reduction at 72 weeks.
- SURPASS trials showed superior HbA1c reduction versus semaglutide in head-to-head diabetes comparisons.
- Pharmaceutical tirzepatide is EMA-approved and prescription-only in Europe; research-grade powder is a separate, unapproved product category.
- Research-grade material requires reconstitution and COA verification; purity and sterility vary by vendor and batch.
Research peptide vs pharmaceutical Mounjaro
The tirzepatide molecule sold by EU research vendors is the same peptide as Mounjaro/Zepbound. However, pharmaceutical Mounjaro is produced under GMP conditions with rigorous quality controls, specific excipients, sterility testing, and known dosing in pre-filled auto-injectors. Research-grade tirzepatide is a lyophilized powder requiring reconstitution, with purity and sterility that varies by vendor and batch.
What does the research show?
Molecular information
Pharmacokinetics
Compare Tirzepatide prices across EU suppliers
COA-verified · Multiple EU vendors · Updated monthly
Frequently asked questions
What is tirzepatide? ▾
Tirzepatide is a once-weekly peptide that activates two incretin receptors — GLP-1 and GIP. It is the active molecule in the approved medicines Mounjaro (type 2 diabetes) and Zepbound (obesity).
Is research-grade tirzepatide the same as Mounjaro? ▾
It is the same peptide molecule, but not the same product. Mounjaro and Zepbound are made under GMP conditions with sterility testing, defined excipients and pre-filled injectors. Research-grade tirzepatide is a lyophilised powder of variable purity sold for laboratory research only.
Is tirzepatide legal in the EU? ▾
The pharmaceutical (Mounjaro/Zepbound) is EMA-approved and available on prescription. Research-grade tirzepatide is sold as a research chemical for laboratory use and is not a substitute for the approved medicine.
How effective was tirzepatide in trials? ▾
The SURMOUNT-1 trial reported mean weight reductions of roughly 16–22.5% across doses at 72 weeks. In diabetes trials (SURPASS) it produced larger HbA1c reductions than semaglutide in head-to-head comparisons.
How does tirzepatide compare to semaglutide? ▾
Tirzepatide adds GIP receptor activity on top of GLP-1. In direct trials it produced greater weight loss and HbA1c reduction than semaglutide, though individual response varies and side-effect profiles overlap.
What are the common side effects? ▾
Predominantly gastrointestinal — nausea, diarrhoea, vomiting and constipation — usually mild to moderate and most common during dose escalation.
What should I check on a tirzepatide COA? ▾
Look for a batch-matched certificate stating HPLC purity (ideally ≥98%), mass-spec identity, and the testing laboratory's name. Sterility cannot be assumed for research powder.
Should I use research tirzepatide instead of a prescription? ▾
No. If you have a medical indication, the approved pharmaceutical via a physician is the appropriate route. Research-grade material is for laboratory research and is not quality-controlled for human use.
Why do tirzepatide prices vary between EU suppliers? ▾
Vial size, claimed purity and supplier overheads all differ. PeptideCompare normalises this to price per mg so equivalent products can be compared fairly.
References
- SURMOUNT-1 Phase 3 obesity trial reporting up to ~22.5% weight reduction at 72 weeks. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205–216. DOI PubMed 35658024
- SURMOUNT-2 Phase 3 trial in adults with type 2 diabetes and obesity. Garvey WT, et al. Lancet. 2023;402(10402):613–626. DOI PubMed 37385275